A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

Also called NCT03131687

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 318 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03131687
  • EudraCT 2016-004179-33
Other papers using this trial's data
  • Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Diabetes care, 2020-06 DOI, PubMed 32291277, PMC7245348 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes The Journal of clinical endocrinology and metabolism, 2022-01-18 DOI, PubMed 34608929
  • Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet (London, England), 2018-11-17 DOI, PubMed 30293770

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Poland, Puerto Rico, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03131687. Randomized; double masking; primary purpose treatment. Start 2017-05-24 (actual); primary completion 2018-08-01 (actual). Results posted on 2019-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
tirzepatide
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03131687
Content hash
1e2a21c1e56829a58735f53f7a0539655a428fcf9d1f5f8404dc773ac191046c